ConductScience.org, home
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
API referenceFor AI assistants

Trial · NCT02257567

Adverse event totals33

The totals the trial posted for each group.

1 to 20 of 33

Download this page as JSON
TotalGroupAffectedAt risk
Total, all-cause mortalityCohort 1a (Phase Ib Safety Run-In): Pola+BR in FL26
Total, all-cause mortalityCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL26
Total, all-cause mortalityCohort 1b (Phase Ib Safety Run-In): Pola+BG in FL26
Total, all-cause mortalityCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL46
Total, all-cause mortalityArm A (Phase II Randomization): Pola+BR in FL1639
Total, all-cause mortalityArm B (Phase II Randomization): BR in FL1141
Total, all-cause mortalityArm C (Phase II Randomization): Pola+BR in DLBCL2640
Total, all-cause mortalityArm D (Phase II Randomization): BR in DLBCL3040
Total, all-cause mortalityArm E (Phase II Expansion): Pola+BG in FL320
Total, all-cause mortalityArm F (Phase II Expansion): Pola+BG in DLBCL1821
Total, all-cause mortalityArm G+H (Phase II NF Cohort): Pola+BR in DLBCL65106
Total, other adverse eventsCohort 1a (Phase Ib Safety Run-In): Pola+BR in FL66
Total, other adverse eventsCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL66
Total, other adverse eventsCohort 1b (Phase Ib Safety Run-In): Pola+BG in FL66
Total, other adverse eventsCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL66
Total, other adverse eventsArm A (Phase II Randomization): Pola+BR in FL3838
Total, other adverse eventsArm B (Phase II Randomization): BR in FL3941
Total, other adverse eventsArm C (Phase II Randomization): Pola+BR in DLBCL3639
Total, other adverse eventsArm D (Phase II Randomization): BR in DLBCL3739
Total, other adverse eventsArm E (Phase II Expansion): Pola+BG in FL2020

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02257567/event-totals

API referenceFor AI assistants